Aperio Group LLC lifted its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 9.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 345,539 shares of the medical research company’s stock after acquiring an additional 31,185 shares during the period. Aperio Group LLC owned about 0.09% of Thermo Fisher Scientific worth $65,376,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Proficio Capital Partners LLC raised its position in shares of Thermo Fisher Scientific by 71.5% during the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after acquiring an additional 253 shares in the last quarter. Chicago Partners Investment Group LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $108,000. Cribstone Capital Management LLC raised its position in shares of Thermo Fisher Scientific by 8.7% during the 2nd quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after acquiring an additional 50 shares in the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $113,000. Finally, Ropes Wealth Advisors LLC raised its position in shares of Thermo Fisher Scientific by 15.8% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 97 shares in the last quarter. 83.78% of the stock is currently owned by institutional investors and hedge funds.
Thermo Fisher Scientific Inc (NYSE:TMO) opened at $190.17 on Friday. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $201.20. The stock has a market capitalization of $76,030.00, a price-to-earnings ratio of 20.78, a PEG ratio of 1.73 and a beta of 1.08. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The company had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. During the same quarter in the prior year, the business posted $2.03 earnings per share. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. research analysts expect that Thermo Fisher Scientific Inc will post 9.36 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be paid a $0.15 dividend. The ex-dividend date is Thursday, December 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.32%. Thermo Fisher Scientific’s payout ratio is 10.19%.
A number of brokerages recently commented on TMO. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, September 18th. Bank of America Corporation restated a “buy” rating and set a $210.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. BidaskClub downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Barclays PLC restated an “overweight” rating and set a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Finally, Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus price target of $205.71.
TRADEMARK VIOLATION NOTICE: This report was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://stocknewstimes.com/2017/11/18/aperio-group-llc-boosts-position-in-thermo-fisher-scientific-inc-tmo.html.
In related news, VP Seth H. Hoogasian sold 4,140 shares of the firm’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $177.80, for a total transaction of $736,092.00. Following the completion of the transaction, the vice president now owns 25,518 shares of the company’s stock, valued at $4,537,100.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total value of $9,419,500.00. Following the transaction, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The disclosure for this sale can be found here. Insiders have sold 60,420 shares of company stock valued at $11,308,477 in the last ninety days. Company insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.